DUBLIN, Ohio--(BUSINESS WIRE)--April 11, 2006--Neoprobe Corporation (OTCBB:NEOP - News), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has completed a submission to FDA to respond to information requested by FDA regarding both preclinical toxicity studies and the chemistry, manufacturing and control (CMC) issues surrounding the commercial production of Lymphoseek(TM), a compound being developed by Neoprobe. The submission to FDA included characterization studies of the drug substance, testing protocols and testing validation studies of the final drug product. Lymphoseek is intended to be used as a lymphatic tissue targeting agent in biopsy procedures for the detection of lymph nodes in breast and melanoma cancers.
